ADC Therapeutics SA is rated a Strong Buy due to its pivotal ZYNLONTA combination trials for second-line relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The phase 3 LOTIS-5 trial topline data, combining ZYNLONTA with rituximab, is anticipated in Q2 2026 and represents a key milestone. Additionally, the phase 1b LOTIS-7 trial combining ZYNLONTA with glofitamab has shown an 89.8% overall response rate and 77.6% complete response rate, with more data expected by the end of 2026. The company’s $231 million cash runway extends into 2028, reducing near-term dilution risk and supporting ongoing clinical development.
A three-day online training on Pharmaceutical Regulatory Affairs in Asia is scheduled for October 20-22, 2026, aiming to help professionals understand diverse regulatory requirements across major Asian markets including China, India, Korea, and ASEAN...
The global workwear market, valued at $265.12 billion in 2025, is expected to grow to $344.71 billion by 2031 with a 4.5% CAGR. Growth is fueled by rising corporate employment worldwide, especially in Asia-Pacific, and increased focus on professional...
The global microalgae-based aquafeed market is projected to grow from $320 million in 2026 to $481 million by 2031, at an 8.5% CAGR. Key growth drivers include rapid cost reductions in closed photobioreactor farming, making algae competitive with fis...
The global consumer finance market is projected to expand from $9.87 trillion in 2025 to $14.08 trillion by 2031, growing at a 6.17% CAGR. Key growth drivers include embedded finance at point-of-sale, which boosts credit uptake by integrating lending...
Xcel Brands has signed a licensing agreement with KBL Group to produce ready-to-wear collections for OFF/DUTY by Coco Rocha, a fashion brand created with supermodel Coco Rocha. KBL Group will handle sourcing, product development, manufacturing, and s...
